Patients with type 2 diabetes and without a history of cardiovascular or renal events who were prescribed vildagliptin plus metformin therapy had reductions in mean fasting plasma glucose levels, mean body mass index and postprandial glucose and reported fewer hypoglycemic events 24 weeks after receiving the antimalarial drug hydroxychloroquine, compared with those on canagliflozin, according to a study presented at the American Association of Clinical Endocrinologists annual meeting. Indian researchers recruited 87 patients, mean age of 56, and found that the hydroxychloroquine group also had a greater reduction in high-sensitivity C-reactive protein than the canagliflozin group.
Hydroxychloroquine tied to improved glycemic control in diabetes
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.